References
- Lewis DFV. Cytochromes P450: Structure, function and mechanism. Taylor & Francis, London 1996
- Lewis DFV. Guide to cytochromes P450 structure and function. Taylor & Francis, London 2001
- Lewis DFV. 57 varieties: The human cytochromes P450. Pharmacogenomics 2004; 5: 305–318
- Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: A status report summarizing their reactions, substrate, inducers and inhibitors. Drug Met Rev 1997; 29: 413–580
- Rendic S. Summary of information on human CYP enzymes: Human P450 metabolism data. Drug Met Rev 2002; 34: 83–448
- Lewis DFV, Eddershaw PJ, Goldfarb PS, Tarbit MH. Molecular modelling of CYP3A4 from an alignment with CYP102: Identification of key interactions between putative active site residues and CYP3A-specific chemicals. Xenobiotica 1996; 6: 1067–1086
- Lewis DFV, Lake BG, Dickins M, Goldfarb PS. Homology modelling of CYP3A4 from the CYP2C5 crystallographic template: Analysis of typical CYP3A4 substrate interactions. Xenobiotica 2004; 34: 549–569
- Lewis DFV. Quantitative Structure–Activity relationships (QSARs) for substrates of human cytochromes P450 CYP2 family enzymes. Tox in Vitro 2004; 18: 89–97
- Lewis DFV, Jacobs MN, Dickins M. The importance of compound lipophilicity for substrate binding to human P450s involved in drug metabolism. DDT 2004; 9: 530–537
- Lewis DFV, Dickins M. Baseline lipophilicity relationships in human cytochromes P450 associated with drug metabolism. Drug Met Rev 2003; 35: 1–18
- Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. A comparison of the effects of 3-hydroxy-3-methylgutaryl-coenzyme A (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Met Disp 2001; 29: 282–288
- Stresser DM, Blanchard AP, Turner SD, Erve JCL, Dandeneau AA, Miller VP, Crespi CL. Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Met Disp 2000; 28: 1440–1448
- Ekins S, Stresser DM, Williams JA. In vitro and pharmacophore insights into CYP3A enzymes. TIPS 2003; 24: 161–166
- Riley RJ, Parker AJ, Trigg S, Manners CN. Development of generalized, quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001; 18: 652–655
- Hansch C, Leo A, Hoekman D. Exploring QSAR: hydrophobic electronic and steric constants. Am Chem Soc 1995.
- Ekins S, Bravi G, Binkley S, Gillespie JS, Ring BJ, Wikel JH, Wrighton SA. Three-dimensional quantitative Structure–Activity relationship (3D-QSAR) analysis of inhibitors of CYP3A4. J Pharm Exp Ther 1999; 290: 429–438
- Yano JK, Wester MR, Schoch GA, Giffin KJ, Stout CD, Johnson EF. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05Å resolution. J Biol Chem 2004; 279: 38091–38094
- Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, Jhoti H. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004; 305: 683–686
- Cortes A, Cascante M, Cardenas ML, Cornish-Bowden A. Relationships between inhibition constants, inhibitor concentrations for 50% inhibition and types of inhibition: New ways of analyzing data. Biochem J 2001; 357: 263–268
- Domanski TL, Halpert JR. Analysis of mammalian cytochrome P450 structure and function by site-directed mutagenesis. Curr Drug Met 2001; 2: 117–137
- Atkins WM. Implications of the allosteric kinetics of cytochrome P450s. DDT 2004; 9: 478–484